Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, an enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A into mevalonate, which is a cholesterol precursor.


Riglodem 10 mg: each film-coated tablet contains:

  • Rosuvastatin calcium BP eq. rosuvastatin 10 mg;
  • Dye: iron oxide red and titanium dioxide BP.

Riglodem 20 mg: each film-coated tablet contains:

  • Rosuvastatin calcium BP eq. rosuvastatin 20 mg;
  • Dye: iron oxide red and titanium dioxide.
  • primary hypercholesterolemia (type IIa, including familial heterozygous hypercholesterolemia) or mixed hypercholesterolemia (type IIb) as an adjunct to diet when diet and other non-drug treatments (eg, exercise, weight loss) are insufficient;
  • familial homozygous hypercholesterolemia as an adjunct to diet and other cholesterol-lowering therapy (eg, LDL apheresis), or in cases where such therapy is not suitable for the patient;
  • prevention of cardiovascular complications in adult patients with an increased risk of developing atherosclerotic cardiovascular disease as an adjuvant therapy.

Inside, do not chew or crush the tablet, swallow it whole with water. Can be prescribed regardless of meals.

Before and during therapy with Riglodem, the patient should follow a standard lipid-lowering diet. The dose of the drug should be individualized depending on the goals of therapy and response to treatment, taking into account current recommendations for target lipid concentrations.

The recommended starting dose for patients starting to take the drug, or for patients switching from taking other HMG-CoA reductase inhibitors, should be 5 or 10 mg of Riglodem once daily.

When choosing an initial dose, cholesterol levels should be taken into account and the possible risk of cardiovascular complications should be taken into account, and the potential risk of side effects should be assessed. If necessary, the dose can be increased after 4 weeks of taking the drug. Increase the dose of the drug gradually.